
The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung …
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal …
Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy …
The New England Journal of Medicine
The New England Journal of Medicine
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
5 days ago · Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; …
Critical Illness in an Adolescent with Influenza A (H5N1) Virus ...
Dec 31, 2024 · Influenza A(H5N1) viruses are an emerging zoonotic threat and have spread widely throughout birds in North America. Recently, influenza A(H5N1) infection led to serious illness in a …
Lorundrostat Efficacy and Safety in Patients with Uncontrolled ...
Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous ...
Jun 22, 2025 · In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa...
First-Line Camizestrant for Emerging - The New England Journal of …
Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced …